ATE451835T1 - Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae - Google Patents

Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Info

Publication number
ATE451835T1
ATE451835T1 AT00965349T AT00965349T ATE451835T1 AT E451835 T1 ATE451835 T1 AT E451835T1 AT 00965349 T AT00965349 T AT 00965349T AT 00965349 T AT00965349 T AT 00965349T AT E451835 T1 ATE451835 T1 AT E451835T1
Authority
AT
Austria
Prior art keywords
patient
compositions
viruses
protein
therapeutic methods
Prior art date
Application number
AT00965349T
Other languages
English (en)
Inventor
Stephen J Russell
Roberto Cattaneo
Kah-Whye Peng
Urs Schneider
Anthea L Murphy
Original Assignee
Mayo Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mayo Foundation filed Critical Mayo Foundation
Application granted granted Critical
Publication of ATE451835T1 publication Critical patent/ATE451835T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/485—Epidermal growth factor [EGF], i.e. urogastrone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT00965349T 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae ATE451835T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15587399P 1999-09-24 1999-09-24
PCT/US2000/026116 WO2001020989A1 (en) 1999-09-22 2000-09-22 Therapeutic methods and compositions using viruses of the recombinant paramyxoviridae family

Publications (1)

Publication Number Publication Date
ATE451835T1 true ATE451835T1 (de) 2010-01-15

Family

ID=22557120

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00965349T ATE451835T1 (de) 1999-09-24 2000-09-22 Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae

Country Status (6)

Country Link
EP (1) EP1217891B1 (de)
AT (1) ATE451835T1 (de)
AU (1) AU7607900A (de)
CA (1) CA2383276A1 (de)
DE (1) DE60043547D1 (de)
WO (1) WO2001020989A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241617B2 (en) 1998-07-03 2007-07-10 Dnavec Research, Inc. Sendai viral vectors comprising foreign genes inserted between the R1 and R2 Loci
CA2322057A1 (en) 2000-05-18 2001-11-18 Dnavec Research Inc. Paramyxovirus vectors used for transfer of foreign genes
JP4448440B2 (ja) 2002-04-30 2010-04-07 株式会社ディナベック研究所 プロテアーゼ依存性トロピズムが改変されたベクター
EP1549672B1 (de) * 2002-05-03 2010-09-01 Mayo Foundation For Medical Education And Research Reduzierter slam abhängiger zell eintritt
ES2565496T3 (es) 2003-01-14 2016-04-05 Dana-Farber Cancer Institute Sensibilizador a la terapia para el cáncer
WO2004111249A2 (en) * 2003-06-13 2004-12-23 Polymun Scientific Immunbiologische Forschung Gmbh Protein constructs containing caspase recognition sites
ATE545699T1 (de) 2003-06-18 2012-03-15 Genelux Corp Modifizierte, rekombinante vacciniaviren und deren verwendungen
CA2545024A1 (en) * 2003-11-24 2005-06-02 Novo Nordisk A/S Fusion proteins and methods of cleavage of such proteins
CA2554198A1 (en) * 2004-01-22 2005-08-04 Dnavec Research Inc. Process for producing virus vector
AU2006249235B2 (en) 2004-05-14 2010-11-11 Abraxis Bioscience, Llc Sparc and methods of use thereof
US8420603B2 (en) 2004-05-14 2013-04-16 Abraxis Bioscience, Llc SPARC and methods of use thereof
WO2006050984A2 (en) 2004-11-12 2006-05-18 Bayer Schering Pharma Aktiengesellschaft Recombinant newcastle disease virus
CA2598510C (en) 2005-02-18 2011-12-20 Abraxis Bioscience, Inc. Q3 sparc deletion mutant and uses thereof
JP5603012B2 (ja) 2005-12-02 2014-10-08 トヘ モウント シナイ スクール オフ メディシネ オフ ニューヨーク ウニベルシトイ 非天然表面タンパク質を提示するキメラウイルス及びその使用
EP2097517B1 (de) 2006-10-16 2014-06-04 Genelux Corporation Rekombinantes Lister-Stamm Vaccinia Virus kodierend für einen einzelkettigen anti-VEGF Antikörper
EP2188376A4 (de) * 2007-09-11 2013-07-10 Sapphire Energy Inc Molekülproduktion mittels photosynthetischer organismen
EP2085092A1 (de) 2008-01-29 2009-08-05 Bayer Schering Pharma Aktiengesellschaft Abgeschwächte onkolytische Paramyxoviren zur Kodierung von Vogel-Zytokinen
EP2085479A1 (de) 2008-01-31 2009-08-05 Institut Pasteur Reverse Genetik von Negativstrang-RNA-Viren in Hefe
US20090208495A1 (en) * 2008-02-14 2009-08-20 Bayer Schering Pharma Ag Anti-tumor effective paramyxovirus
WO2010091262A1 (en) 2009-02-05 2010-08-12 Mount Sinai School Of Medicine Of New York University Chimeric newcastle disease viruses and uses thereof
CA2799076A1 (en) * 2010-06-10 2011-12-15 Intervet International B.V. Anti-tumor composition
AU2013212066B2 (en) * 2012-01-26 2018-11-08 Life Technologies Corporation Methods for increasing the infectivity of viruses
CN108977412A (zh) 2012-01-26 2018-12-11 生命科技公司 用于提高病毒感染性的方法
MD4655C1 (ro) 2013-03-14 2020-06-30 Icahn School Of Medicine At Mount Sinai Virusurile bolii de Newcastle şi utilizarea acestora
DK3041490T3 (en) * 2013-09-03 2019-03-04 Medimmune Ltd COMPOSITIONS CONTAINING AN INCREASED NEWCASTLE DISEASE VIRUS AND PROCEDURES FOR USING NEOPLASY TREATMENT
EP3110443A4 (de) 2014-02-27 2017-11-15 Viralytics Limited Kombinationsverfahren zur behandlung von krebs
EP3242939A4 (de) * 2015-01-05 2018-10-17 Seagull BioSolutions Pvt. Ltd. Dna-moleküle zur herstellung individuell gestalteter replizierender und nicht-replizierenden, negativsträngiger rna-viren und verwendungen davon
JOP20190256A1 (ar) 2017-05-12 2019-10-28 Icahn School Med Mount Sinai فيروسات داء نيوكاسل واستخداماتها
US11191826B2 (en) 2017-05-16 2021-12-07 Mayo Foundation For Medical Education And Research Modified viruses
WO2020037215A1 (en) 2018-08-17 2020-02-20 Icahn School Of Medicine At Mount Sinai Recombinant newcastle disease viruses and uses thereof for the prevention of rsv disease or human metapneumovirus disease
WO2025088124A1 (en) 2023-10-27 2025-05-01 Boehringer Ingelheim International Gmbh Novel assay for determining infectious virus titer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9514368D0 (en) 1995-07-13 1995-09-13 Medical Res Council Improvements in or relating to binding assays
DE69510207T3 (de) * 1995-08-09 2007-02-15 Schweiz. Serum- & Impfinstitut Bern Verfahren zur Herstellung von infektiösen minussträngigen RNA-Viren
US6264957B1 (en) * 1995-09-27 2001-07-24 The United States Of America As Represented By The Department Of Health And Human Services Product of infectious respiratory syncytial virus from cloned nucleotide sequences

Also Published As

Publication number Publication date
WO2001020989A9 (en) 2002-10-03
EP1217891A1 (de) 2002-07-03
WO2001020989A1 (en) 2001-03-29
CA2383276A1 (en) 2001-03-29
DE60043547D1 (de) 2010-01-28
EP1217891A4 (de) 2004-05-12
EP1217891B1 (de) 2009-12-16
AU7607900A (en) 2001-04-24

Similar Documents

Publication Publication Date Title
ATE451835T1 (de) Therapeutische verfahren und zusammensetzungen unter verwendung von viren der rekombinanten familie der paramyxoviridae
ATE231549T1 (de) Verfahren zur konservierung von infektiösen rekombinierenden viren, virale wässrige suspension und ihre medizinische verwendung
Sambhi et al. Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo.
Merigan et al. Purification and characterization of vertebrate interferons
ATE91630T1 (de) Pharmazeutische zusammensetzung zur verhuetung oder heilung von durch den papillomavirus induzierten tumoren.
DE69914932D1 (de) Verwendung eines zytokine-produzierenden lactococcus stammes zur behandlung von kolitis
NO20013701D0 (no) HER-2/neu-fusjonsproteiner
DE69835085D1 (de) Regulation der transcription in säugetierzellen und viraler replikation durch eine tetracyclinrepressor
DK1266006T3 (da) Fremstilling af rekombinante muteiner af blodkoagulationsfaktor VIII i humane cellelinier
ATE335831T1 (de) Nukleinsäurevektor, einen solchen vektor enthaltene verbindung und impfstoff zur immunisierung gegen hepatitis
RU95115239A (ru) Аналог эритропоэтина
RU2001117230A (ru) Пептиды, ингибирующие трансформирующий фактор роста tgf$$$1
DK1749836T3 (da) Rekombinant vaskulær endothelcellevækstfaktor D
WO1995026411A3 (en) Composition and methods for creating syngeneic recombinant virus-producing cells
JP2014509197A (ja) 標的性治療人腫瘍治療の腫瘍溶解性アデノウイルス及びその応用
DE69534600D1 (de) Nukleotid- und aminosäuresequenzen der gene des hüllproteins 1 und des kernproteins von hepatitis c virus
DK11187D0 (da) Dna-sekvenser der koder for proteiner med husi-type i inhibitorers biologiske aktivitet, biotekniske fremgangsmaader til fremstilling af proteinerne o g farmaceutiske praeparater der indeholder dem
CY1107431T1 (el) Σωματιδια για γoνιδιακη θεραπεια
ATE349225T1 (de) Apo b, annexin v und tubulin: medizinische und diagnostische verwendung und verwendung zur purifikation von hcv
GB2161487A (en) Interferon epsilon
DE69627526D1 (de) Rekombinantes pockenvirus der infektiösen peritonitis der katze, dessen zusammensetzungen und methoden zur herstellung und verwendung
Hofacre et al. Efficient therapeutic protein expression using retroviral replicating vector with 2A peptide in cancer models
IE870507L (en) Bovine virus diarrhea and hog cholera vaccines
Ahmed et al. In vivo tumor suppression by adenovirus-mediated interferon alpha2b gene delivery
Norton et al. Expression of secreted platelet-derived growth factor-B by recombinant nonreplicating and noncytopathic vaccinia virus

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties